"A growing breast mass led to the discovery of not only a rare malignancy but also an independent, early-stage colon cancer, highlighting the critical importance of comprehensive medical evaluations and proactive cancer screening."
A 59-year-old woman, previously in good health and college-educated, presented to an emergency department with a concerning breast mass that had been steadily enlarging over the preceding 18 months. Her medical history revealed a significant gap in healthcare engagement, as she had not consulted a physician for two decades. This prolonged absence from routine medical care, while not immediately apparent as a risk factor, ultimately underscored the potential for hidden health issues to develop undetected. The initial presentation, marked by the visibly growing breast anomaly, initiated a cascade of diagnostic procedures that would unexpectedly uncover a second, distinct malignancy.
The initial biopsy of the breast mass revealed it to be a malignant phyllodes tumor, a rare and potentially aggressive form of breast cancer. Phyllodes tumors are distinct from more common breast cancers like ductal or lobular carcinomas. They originate from the connective tissues of the breast, known as the stroma, rather than the milk ducts or glands. This distinction in origin contributes to their unique behavior and treatment considerations. While the majority of phyllodes tumors are benign, a significant minority, estimated between 15% and 30%, can be malignant. These malignant variants, like the one identified in this patient, possess the potential for rapid growth and, in some cases, metastasis.
The case, meticulously documented by surgeons Thomas J. Sorenson and Nikhil Agrawal from NYU Langone Health’s Hansjorg Wyss Department of Plastic Surgery, was published in the esteemed Oxford Medical Case Reports in May 2026. Their report details the patient’s journey through diagnosis and treatment, culminating in a positive one-year follow-up where she was declared healthy and disease-free. This outcome, while encouraging, serves as a powerful reminder of the complexities inherent in cancer diagnosis and management.
A Rare Breast Tumor That Pushed Through the Skin
Phyllodes tumors, though rare, represent a distinct category of breast neoplasms. They are characterized by their stromal component, which can be benign, borderline, or malignant. The malignant classification signifies the presence of cellular abnormalities that suggest a potential for uncontrolled growth and invasion. While typically measuring around 4 centimeters in median size, some phyllodes tumors can grow to be substantially larger, exceeding 10 centimeters. The patient’s tumor was described as "exophytic," meaning it grew outward from the body, rather than inward into the breast tissue. This outward growth pattern, while not a separate subtype, is often associated with aggressive behavior and can present unique challenges for surgical management. Exophytic tumors are prone to ulceration and bleeding, further complicating their removal and potentially increasing the risk of infection.
The management of large, exophytic phyllodes tumors often requires extensive surgical intervention. The overlying skin may become compromised, and the natural architecture of the breast can be significantly distorted. Consequently, surgeons typically need to perform a wide local excision or, more commonly, a radical mastectomy to achieve clear surgical margins – the crucial absence of cancer cells at the edges of the resected tissue. Following the removal of the tumor, reconstructive procedures or radiation therapy may be necessary to restore form and function and to eliminate any residual microscopic disease. In this patient’s case, surgeons opted for a radical mastectomy, confirming clear margins during the operation. The resulting chest wound was then expertly covered using a local tissue flap, a common reconstructive technique that utilizes nearby healthy tissue to close the defect.
The Second Cancer Surfaced During the Workup
The discovery of a second, unrelated cancer during the diagnostic workup for the breast mass underscores the critical importance of thoroughness in cancer evaluation. As part of the comprehensive assessment and to rule out distant spread of the breast cancer, the patient underwent a Positron Emission Tomography (PET) scan and a colonoscopy. The PET scan, which highlights areas of increased metabolic activity often associated with cancer, indicated no signs of the breast cancer having metastasized to distant organs. However, it did reveal heightened activity in the descending colon, located on the left side of the abdomen. While PET scans are valuable screening tools, they are not definitive for cancer diagnosis; increased sugar uptake can be indicative of various conditions, including inflammation.
The subsequent colonoscopy, a direct visual examination of the colon, identified a mass in the descending colon. Further pathological examination confirmed this mass to be an early-stage primary colon adenocarcinoma. This diagnosis was significant because it represented a separate and distinct cancer that originated in the colon itself, not a metastasis from the breast tumor. The successful management of both malignancies involved sequential surgical interventions. After the chest wound was addressed, surgeons proceeded with a curative left hemicolectomy, a procedure involving the removal of the left half of the colon where the tumor was located.
The case report does not suggest any causal relationship between the breast tumor and the colon cancer. There was no mention of genetic testing that might link the two. Instead, the authors emphasize the value of a comprehensive diagnostic approach. When a patient presents with a serious diagnosis that is not immediately life-threatening, a thorough total-body assessment and appropriate cancer screenings are paramount. Such an approach can uncover other, potentially silent, primary cancers that might otherwise go undetected until they reach a more advanced stage.
Twenty Years Without a Checkup Meant Missed Screening Years
The patient’s delayed presentation for medical care meant she missed crucial opportunities for routine cancer screenings, particularly for colorectal cancer. For women in her age group, colorectal cancer screening is considered standard preventive care. The U.S. Preventive Services Task Force (USPSTF) recommends screening for all adults between the ages of 45 and 75, a guideline that was updated in 2021 to lower the starting age from 50. A variety of screening methods are available, including annual stool tests, stool DNA tests every one to three years, CT colonography every five years, and colonoscopy every ten years. Any abnormal result from a non-colonoscopy screening test necessitates a follow-up colonoscopy for definitive diagnosis.
While a single case study cannot definitively prove whether earlier screening would have altered the patient’s outcome, her colon cancer was indeed detected at an early stage, with no evidence of distant spread on her PET scan. Her successful treatment and subsequent recovery illustrate the benefit of early detection. However, the case starkly highlights how cancers can remain hidden when individuals are not engaged in regular contact with the healthcare system. Colorectal cancer continues to be a significant cause of cancer-related mortality in the United States. The American Cancer Society estimates that in 2026, there will be approximately 158,850 new cases of colon and rectal cancer combined, leading to an estimated 55,230 deaths. The power of screening lies in its ability to detect cancer at its nascent stages, when treatment is most effective. Furthermore, during a colonoscopy, precancerous polyps can be identified and removed, preventing them from ever developing into cancer, according to the National Cancer Institute.
What the Case Does and Does Not Show
This report, being a single case study, offers valuable insights but also has limitations. It does not provide a detailed staging of the colon cancer beyond classifying it as early-stage, nor does it delve into the specific reasons behind the patient’s prolonged avoidance of medical care. The follow-up period of one year, while showing a positive immediate outcome, is insufficient to fully assess the long-term prognosis. Malignant phyllodes tumors, like other cancers, have the potential to recur, and longer-term follow-up is essential for a comprehensive evaluation of her overall outcome.
Despite these limitations, the practical messages derived from this case are clear and actionable. Any breast lump that demonstrates persistent growth, regardless of pain or other symptoms, warrants prompt medical attention. For adults aged 45 and older who are not up-to-date on their colorectal cancer screening, consulting a healthcare provider to determine the most appropriate screening method is crucial. Furthermore, individuals experiencing concerning symptoms such as rectal bleeding, persistent changes in bowel habits, or unexplained weight loss should not delay seeking medical advice, even if they are not due for a routine screening appointment.
Key Questions Answered
What happened in this case?
A 59-year-old woman presented with a breast mass that had been growing for 18 months. Diagnosed with a malignant phyllodes tumor, further investigations during her workup also revealed an independent, early-stage colon cancer.
What is a phyllodes tumor?
A phyllodes tumor is a rare type of breast tumor that arises from the connective and glandular tissues of the breast, accounting for less than 1% of all breast tumors. While most are benign, approximately 15% to 30% are malignant.
How was the colon cancer found?
During her diagnostic workup for the breast mass, which included a PET scan and a colonoscopy, increased activity was noted in the descending colon. A subsequent colonoscopy identified a mass, which was confirmed to be an early colon adenocarcinoma.
How was she treated?
The patient underwent a radical mastectomy for the breast cancer, with the chest wound closed using a local tissue flap. She then had a curative left hemicolectomy to remove the cancerous portion of her colon. One year later, she was disease-free.
Did one cancer cause the other?
The report does not suggest any causal link between the breast tumor and the colon cancer. The discovery of the second cancer is attributed to the thoroughness of the diagnostic evaluation.
When should people get screened for colorectal cancer?
The U.S. Preventive Services Task Force recommends colorectal cancer screening for adults aged 45 to 75. Individuals experiencing symptoms should consult a clinician promptly, without waiting for a scheduled screening.
